REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Conference Call Information
When: Wednesday, August 2nd, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI3fdbdc05783442f89d11db6b94e74a28
Webcast: https://edge.media-server.com/mmc/p/irz4npdq
The press release with the second quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.
Please dial-in 15 minutes early to ensure a timely connection to the call.
Coherus Contact Information:
Marek Ciszewski, J.D.
SVP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$1.20 |
| Daily Change: | -0.03 -2.44 |
| Daily Volume: | 2,030,828 |
| Market Cap: | US$145.040M |
December 08, 2025 November 07, 2025 November 06, 2025 November 06, 2025 August 07, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load